(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 7.73% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.76%.
Neogenomics's revenue in 2025 is $689,189,000.On average, 7 Wall Street analysts forecast NEO's revenue for 2025 to be $93,824,629,195, with the lowest NEO revenue forecast at $93,110,658,951, and the highest NEO revenue forecast at $96,496,430,634. On average, 7 Wall Street analysts forecast NEO's revenue for 2026 to be $103,586,399,302, with the lowest NEO revenue forecast at $101,857,343,447, and the highest NEO revenue forecast at $107,722,052,886.
In 2027, NEO is forecast to generate $112,490,681,717 in revenue, with the lowest revenue forecast at $110,677,659,757 and the highest revenue forecast at $114,604,689,866.